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1. Introduction 
The natural vitreous is a transparent, gelatinoid structure occupying four-fifths of the 
volume of the eye. It has a thin, membrane-like structure corresponding to the vitreous 
cortex that extends from the ora serrata to the posterior pole.1 It is somewhat spherical but 
slightly flattened meridionally, and it has a cup-shaped depression in its anterior side. It 
consists of about 99% water by weight, collagen fibers (types II, V/XI, VI, and IX), 
hyaluronic acid, opticin, fibrillin, and hyaluronan, which can maintain a certain spatial 
relationship with dipolar water molecules.1,2 However, very few cells are found in the 
vitreous body. These cells are mostly phagocytes that clear useless cellular debris and 
hyalocytes mainly found at the periphery and that produce hyaluronic acid and collagen. In 
human adults, the vitreous body has an approximate weight of 4 g, a density of 1.0053–
1.0089g cm-3, a refractive index of 1.3345–1.3348, and a PH range of 7.0–7.4. 3-5 
The physiological function of the vitreous body involves supporting adjacent posterior 
segment structures, providing an ocular refractive medium, and acting as a cell barrier to 
inhibit cell migration from the retina to the vitreous cavity.6 With age, the natural vitreous 
body gradually shrinks and collapses during the course of syneresis. This phenomenon may 
eventually lead to posterior vitreous detachment and can play a crucial role in the formation 
of retinal breaks which result in rhegmatogenous retinal detachment if untreated.7,8   
The removal of diseased vitreous bodies using pars plana vitrectomy combined with 
artificial vitreous substitutes can restore vision in many patients. These individuals include 
those affected by proliferative diabetic retinopathy, proliferative vitreoretinopathy, and 
endophthalmitis or patients otherwise regarded as hopeless.9-11 
The vitreous body cannot regenerate, so the vitreous cavity must be filled with suitable 
artificial vitreous substitutes that will keep the retina in place and prevent phthisis bulbi. 
Artificial vitreous substitutes are one of the most interesting and challenging topics of 
research in ophthalmology.2 A number of artificial vitreous substitutes, such as gas, silicone 
oil, heavy silicone oil, and hydrogels, have been used.2,12  
There are three major categories of currently available gas vitreous substitutes: air 
substitutes, expansile gas substitutes, and Xenon. Gases are used for pneumatic retinopexy 
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and post-operative endotamponade. However, they are suitable only as short-term vitreous 
substitutes (Table 1).13  
 
 
G 
Molecular 
Weight 
Purity 
(mol%) 
Expansion 
Coefficient 
Duration* 
(day)  
Expansion 
Concentration
(%) 
Air 29 -- 0 5-7 - 
Xenon 131 99.995 0 1 - 
SF6 146 99.9 1.9-2.0 10-14 18 
C2F6  88 99.7 1.9 10-14 - 
C4F8  138 99.9 3.3 30-35 16＋ 
C3F8 188 99.7 4 55-65 14 
Table 1. Physical characteristics of gases as vitreous substitutes 
In 1969, Norton et al. highlighted the advantages of clinical management with intravitreal 
air for the treatment of giant retinal tears.14 However, the intravitreal longevity of air is only 
a few days15 due to diffusion across the retina. The refractive index of the air (1.0008) is also 
incompatible with optically important tissues. Therefore, these issues limit the use of air. To 
date, air is mainly used in liquid–air exchanges during vitrectomy procedures.16 
In 1973, Norton first experimented with sulphur hexafluoride (SF6) and found that the 
persistence of the gas and its expansile characteristics are superior to air. SF6 expands to 
twice its volume by dissolving nitrogen, oxygen, and carbon dioxide from the blood. It also 
stays in the vitreous cavity for about two weeks.17 In 1980, Lincoff et al. proposed the use of 
perfluorocarbon gases18. These gases expand after intravitreal injection because of the 
diffusion of other gases from the blood stream. Perfluoropropane expands to four times its 
original volume by the fourth day after injection. It is also absorbed at a much slower rate 
than air or sulphur hexafluoride. To date, C3F8 is the agent of choice. Expansile gases last 
longer in the vitreous chamber than air, but they are spontaneously absorbed in 6 to 80 days 
and replaced by aqueous humor. Therefore, postsurgical removal is avoided if they cause 
certain concomitant complications.19 However, they may induce lens opacification and 
usually result in a high intraocular pressure (IOP).20,21 As with air, the refractive indices of 
gases are also lower (w1.17).22 
Xenon was tested in rabbit eyes to evaluate its longevity in the vitreous cavity.23 It is 
considered as the most promising gas with successful retinal reattachment in all cases. 
However, the major drawback is its rapid disappearance; almost 90% of Xenon disappears 3 
h after introduction.24 
Silicone oil is hydrophobic, viscous, transparent, and stable. It has a specific gravity of 0.97 
g/mL and a refractive index of 1.4. Its viscosity is measured in centistokes and linearly 
varies with chain lengths and molecular weight. The 1,000 and 5,000 centistoke varieties are 
commonly used in clinics. The surface tension is approximately 40 mN/m. Introduced by 
Cibis in 1962,25 silicone oil has been the most important adjunct for internal tamponade in 
the treatment of complicated retinal or choroidal detachment for the past five decades. It is 
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commonly applied for the treatment of superior retinal detachment through buoyancy force 
and high interfacial tension. It is the only substance currently accepted as a long-term 
vitreous substitute and is the preferred choice in complex retinal detachments, such as long-
standing rhegmatogenous retinal detachment, traction retinal detachment, giant retinal 
tears, proliferative diabetic retinopathy, and severe endoophthalmitis involving the 
posterior segment.  
However, the use of silicone oil has not always been successful. An anatomic success rate of 
around 70% has been reported,19 with complications including cataract, keratopathy, 
anterior chamber oil emulsification, and glaucoma.26 Several reports have demonstrated the 
migration of silicone oil droplets into the retina and the optic nerve. Others have shown the 
widespread loss of myelinated optic nerve fibers due to the oil’s free-fluid characteristics 
within the eye.27, 28  
Heavy oil, a solution of perfluorohexyloctane and silicone oil prepared as internal 
tamponade, has recently been used in retinal detachment surgery. However, it causes 
complications, such as emulsification and inflammatory reaction.29 Some very recent results 
are encouraging,30 but most clinicians are awaiting results from ongoing heavy silicone oil 
trials.12 
Hydrogels and smart hydrogels seem to remain as the best candidates as long-term vitreous 
substitutes because they show excellent transparency and good biocompatibility. They can 
act as viscoelastic shock-absorbing materials, thereby closely mimicking the behavior of 
natural vitreous bodies. Hydrogels are networks of polymer chains that can contain over 
99.9% water so they are hydrophilic and not flowable. Currently, a number of cross-linked 
polymeric hydrogels have been proposed, such as poly (vinyl alcohol) (PVA), poly poly (1-
vinyl-2-pyrrolidone), poly (acrylamide) (PAA), and poly (ethylene glycol) (PEG).2,12,31-34 
Among these, the PVA and PAA hydrogels are the most promising candidates for long-term 
vitreous body replacement and are highly recommended for use. They show excellent 
biocompatibility, are biodegradable, and can closely mimic the physico-mechanical 
properties of natural vitreous bodies.2 PEG is a synthetic water-soluble polymer that has 
been approved by the Food and Drug Administration (FDA) for use in a wide range of 
biomedical applications, including injectable hydrogels.35 However, issues such as retinal 
toxicity, increased IOP, and formation of opacities still need to be addressed.36 
Fragmentation and changes in viscoelastic properties and resiliency after injection through a 
small-gauge needle have also been found in some types of hydrogels.36, 37 
Smart hydrogels are a relatively new class of stimuli-sensitive hydrogels. They possess the 
common properties of conventional hydrogels, and they can respond to a variety of signals, 
including PH, temperature, light, pressure, electric fields, or chemicals.38 Temperature-
sensitive hydrogels, such as poly(N-isopropylacrylamide), the most extensively studied one, 
undergo sharp hydrophilic-hydrophobic transition in aqueous media at a lower critical 
solution temperature of 32 °C, which is close to the body temperature.39 Generally, smart 
hydrogels appear promising, but they are still at an early experimental stage, and their long-
term toxicity is unknown.12 Therefore, despite half a century of research efforts to replace 
the vitreous body of the eye, an ideal and permanent vitreous body replacement has yet to 
be found.40,41 
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Current research on artificial vitreous bodies aims to determine ideal materials that are 
nontoxic and inert, thin and transparent, and have good water and oxygen permeability, 
high compatibility, and good elasticity46 in order to mimic the natural vitreous perfectly. 
The materials must be hydrophilic and can form a gel within the vitreous cavity.35 
However, directly injected vitreous substitutes, like silicon oil and heavy silicon oil, often 
result in severe complications, such as intraocular toxicity, retinal cell proliferation, 
leakage into the anterior chamber, and difficulty of complete removal if emulsified with 
time, among others. 
Inspired by the structure of the natural vitreous, we postulated a novel foldable capsular 
vitreous body (FCVB) to restore the shape and function of the natural vitreous body. The 
FCVB consisted of a capsule, drain tube, and valve. The capsule exactly mimicked the 
vitreous body using a computer. The intra-capsule pressure can be adjusted from the valve 
with a syringe, and there is a slice of anti-penetrating metal in the valve. Figure 1 and Table 
2 show the images and parameters of the FCVB, respectively.50 Silicone rubber elastomer has 
been used for tissue augmentation for many years, 43-45 so it was utilized to manufacture the 
capsule of FCVB. It showed good oxygen permeability, good mechanical and optical 
properties (Shore A hardness: 37.4。, tensile intensity: >5.86 MPa, elongation ratio: >1200%, 
tear intensity: 34KN/m, transmittance: 93%, Hazes<1%),46 and good biocompatibility as 
shown in stable extracts experiment (no significant fever, good genetic safety, and no 
structural abnormality or apoptosis in the cornea, ciliary body, and retina over a six-month 
observation period).50 After pars plana vitrectomy, the seamlessly connected FCVB was 
triple-folded and inserted into the vitreous cavity through a 3 mm × 1 mm scleral incision 
without air fluid exchange. Then an injectable medium, such as balanced salt solution (BSS) 
or silicone oil, can be injected into the capsule and inflated to support the retina. Through 
the tube–valve system, IOP can be adjusted by the volume of the injected medium. Similar 
to the glaucoma valve, the valve can be fixed onto the sclera surface. 46 
 
 
 
 
FCVB, foldable capsular vitreous body; BSS, balanced salt solution. 
Note: The FCVB consisted of capsule, drain tube, and valve.The capsule was mimicking the vitreous 
body exactly by computer, and BSS was injected through the tube-valve system to inflate the capsule. 
Table 2. Standard dimensions of the components of the human FCVB 
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Fig. 1. The human foldable capsular vitreous body (FCVB) consists of vitreous-shape high 
molecular capsule, tube, and valve. The intra-capsule pressure can be adjusted from the 
valve with a syringe and there is a slice of anti-penetrating metal in the valve; the designed 
parameters finely mimic the vitreous shape of a human. (A) Illustration of FCVB. (B) Final 
sample of the FCVB (Outside the eye). (C) Side view of varied parameters. (D) Vertical view 
of varied parameters. (E) FCVB inside the eye (Twelve months after implantation). 
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Theoretically, a new artificial vitreous has the following advantages. First, it does not flow 
into the anterior chamber and subretinal regions or other sites. Second, it does not emulsify 
or damage the media over time nor cause it to be isolated in the capsule. Third, it has the 
capability to support discretionary retina using a 360-degree solid arc.  
Developing an irregular vitreous-shaped thin capsule and smoothly connecting it to a very 
thin diameter tube and a pressure-control valve are very difficult. According to this 
hypothesis, a mirror steel mold is specially designed to fabricate FCVB using an injection-
forming technology that would make the capsule, drainage tube, and valve of the FCVB 
seamlessly connected. The mold consists of an upper composite die, a lower composite die, 
and a core.47 The core shape can be manipulated using a computer to match the human 
vitreous parameters. The capsular film is 60 μm thick, only one-third the thickness of the 
retina. In its natural shape, the human FCVB is somewhat spherical, but it is slightly 
flattened meridionally and has a cup-shaped depression anteriorly. 
In the rabbit model of severe retinal detachment, the BSS-filled FCVB was found to mimick 
the morphology of the natural vitreous very closely and to restore its physiological 
functions, such as support, refraction, and cellular barriers, during a three-month 
observation period and without obvious complications. By contrast, the silicone oil control 
group showed obvious lens opacity, significant hyperopic shift, recurrent retinal 
detachment, preretinal membrane formation, and vitreoretinal traction.48 The FCVB capsule 
can provide the detached retina with a platform to form a flat scar and a barrier to block cell 
migration from the retina to the vitreous cavity. 
Interestingly, the BSS-filled FCVB very slightly changes the refraction compared with 
silicone oil and heavy silicone oil based on Gullstrand–Emsley and Liou–Brennan schematic 
eyes.49 Reports from the State FDA in China show that FCVB has suitably mechanical, 
optical, and biocompatibility properties.50 Its optical characteristics indicate that FCVB has 
high light transmission and laser irradiation stability. 
In the early development of breast implants in plastic surgery, similar to current clinical 
vitreous substitutes, directly injectable materials were used. In fact, hydrophilic 
polyacrylamide gel (PAAG) was directly injected into the breast. This procedure was 
practiced widely in China and Eastern Europe in the 1990s. The breast implantation 
procedure was analogous to the use of silicone oil to replace the vitreous body. However, 
the injected PAAG was gradually found to induce severe complications, such as 
inflammation and infection, multiple indurations, hematoma, painful masses, and 
mastalagia. Currently, the direct injection of PAAG is prohibited, and it has been replaced 
with the use of capsule-like implants whose fluid substitute is contained in a thin, elastic 
capsule. This approach to implantation has shown clinical success.51 In case of severe 
complications, as mentioned above, the implant can be completely removed without leaving 
behind residual fluid substitute. Apparently, the development of both artificial vitreous and 
breast substitutes shared a similar path, and both have suffered setbacks from the direct 
injection of the fluid substitute into the organ. Therefore, similar lessons can be learned, and 
the use of a capsule-type implant may be a good replacement for the use of the vitreous 
body.46 
The use of FCVBs in the eyes is not yet a common practice worldwide. Therefore, an 
exploratory study of our new treatment for severe retinal detachment was conducted. The 
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detachment cannot be easily reattached with silicone oil tamponade, such as posterior 
scleral ruptures with large disruptions of the retina or severe scleral ruptures with retinal 
and choroidal detachments. It may also have rigid retinal redetachments or inferior holes 
occurring after silicone or heavy oil tamponade had been attempted. At Zhongshan 
Ophthalmic Center, 11 patients were implanted with FCVBs filled with BSS,52 whereas 3 
patients were implanted with FCVBs filled with silicone oil.53 Patients with serious eye 
inflammation, with only one eye remaining, with silicone oil-filled eyes, with serious heart, 
lung, liver, or kidney dysfunctions, or have other diseases that make them unsuitable for 
inclusion were excluded from the research. Retinal reattachments were found by B-scan in 8 
(73%) of the 11 eyes at the end of the three-month treatment time; leakage of FCVB caused 
failure in three eyes. The production method of FCVB was correspondingly revised, and this 
addressed the problem. No obvious inflammation was observed in any eye after FCVB 
implantation, and UBM showed that the FCVB did not crush the ciliary body. There was no 
obvious difference between the FCVB’s spectral transmittance before implantation and after 
removal.52 Overall, the results showed that FCVB is an effective and safe artificial vitreous 
body for severe retinal detachments. It can help avoid the complications induced by silicone 
oil, such as glaucoma, corneal keratopathy, and silicone oil emulsification during a 12-
month implantation time.53 
Current data have demonstrated the theoretical advantages of using FCVBs, as mentioned 
above. Even if an ideal injectable material can be found, the use of FCVB is necessary to the 
artificial vitreous body. It acts as a transporter that can be injected with media, such as BSS, 
silicone oil, heavy oil, and hydrogels. In the present research, BSS was injected into the 
capsule of FCVB after PPV, and it was demonstrated as a flexible, effective, and safe 
vitreous substitute over a three-month implantation period.52 Further multiple-central 
clinical trials are in progress in China, and the encapsulation of silicone oil, heavy oil, or 
hydrogels in PPV eyes will be attempted. Some common substances are active, such as 
collagen, hyaloronic acid, water, and the natural vitreous that consists of approximately 99% 
water and 1.0% inorganic salts, organic lipids, and hyaluronan1, so these are not 
recommended as encapsulated tamponades in PPV eyes. 
In addition, tiny (300 nm) apertures (Fig.2)54 exist in the capsule, so the FCVB can release 
dexamethasone sodium phosphate and Protein kinase Cα. It can also be used as an 
intravitreal drug delivery system in addition to serving as a vitreous substitute.54,55 
Therefore, without the need to change its chemical properties, FCVB may provide a 
common vehicle for different drug releases, including antibiotics, anti-proliferative agents, 
and vascular endothelial growth factor antagonists.  
The present exploratory clinical study was not large enough to provide a definitive 
conclusion. Further, the effects of FCVB on the lens should be further evaluated because 10 
of 11 eyes were aphakic, and only one eye was phakic.52 Based on this trial, a nine-hospital 
clinical trial is currently in progress in China to ascertain FCVBs’ safety and efficacy as a 
vitreous substitute. The FCVB produced by Guangzhou Vesber Co. Ltd. is still in the stage 
of clinical trial, so it is not commercially available. 
FCVBs have some similarities to thin elastic capsule breast implants and tissue expander 
systems used in plastic surgery. However, they also have differences, which are as follows. 
(1) Production methods: FCVBs are formed by injection forming technology and have a US 
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patent, whereas capsule breast implants and tissue expander systems are made by dip 
forming for large balloons. (2) Sample size: Producing an irregular vitreous-shaped thin 
capsule and smoothly connecting it to a 1.2 mm diameter tube and a pressure-control valve 
are major challenges. However, capsule breast implants and tissue expander systems are 
large and easily made. (3) Implantation site: FCVBs are implanted into the vitreous cavity 
and come into contact with very tender tissues, such as the retina, ciliary body, lens, and 
anterior chamber. However, capsule breast implants and tissue expander systems directly 
come into contact with adipose tissues. Therefore, there are a number of safety issues in the 
use of FCVBs, which have to be addressed.  
(A)   
(B)   
Fig. 2. Scanning electron microscope images of the capsule of the FCVB. Before implantation 
(A) and at the end of the observation time (B) 300-nm-mili apertures in the capsule were 
observed (arrows). 
www.intechopen.com
 
A Novel Artificial Vitreous Substitute – Foldable Capsular Vitreous Body 
 
315 
In conclusion, a new paradigm for the fabrication of a vitreous body substitute using FCVB 
was proposed in the current work. FCVB was established as an acceptable replacement as it 
closely mimics the morphology and restores the physiological function of the vitreous body. 
This idea provided us with a novel approach in researching on a new therapy strategy 
mimicking the natural vitreous that has been used for nearly half a century. 
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